Skip to search formSkip to main contentSkip to account menu

CI-1033

Known as: CI 1033, CI-1033/PD183805, CI1033 
An orally bioavailable quinazoline with potential antineoplastic and radiosensitizing activities. CI-1033 binds to the intracellular domains of pan… 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (2)

Canertinibcanertinib dihydrochloride
PD 183805

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2010
Review
2010
Modulation of the oncogene-dependent tissue factor expression by kinase suppressor of ras 1.
2008
2008
Clinical stage EGFR inhibitors irreversibly alkylate Bmx kinase.
2007
2007
The pan-erbB tyrosine kinase inhibitor CI-1033 inhibits human esophageal cancer cells in vitro and in vivo.
The epidermal growth factor receptor (EGFR) is a member of the EGFR family of receptors. EGFR and other members of the EGFR… 
2006
2006
Multi-tracer small animal PET imaging of the tumour response to the novel pan-Erb-B inhibitor CI-1033
PurposeThis study was designed as “proof of concept” for a drug development model utilising multi-tracer serial small animal PET… 
2004
2004
A phase 2, single agent study of CI-1033 administered at two doses in ovarian cancer patients who failed platinum therapy.
5054 Background: Ovarian cancer that is refractory to platinum-based therapies is a therapeutic challenge, particularly in the… 
2003
2003
Skin as a surrogate tissue for pharmacodynamic end points: is it deep enough?
As the number of molecular-targeted agents under clinical development keeps growing, it is becoming increasingly evident that it… 
Highly Cited
2002
Highly Cited
2002
Syntheses and EGFR and HER-2 kinase inhibitory activities of 4-anilinoquinoline-3-carbonitriles: analogues of three important 4-anilinoquinazolines currently undergoing clinical evaluation as…
Highly Cited
2001
Highly Cited
2001
Evidence for epidermal growth factor receptor-enhanced chemosensitivity in combinations of cisplatin and the new irreversible tyrosine kinase inhibitor CI-1033
Irreversible inhibitors of the epidermal growth factor receptor (EGFR) are showing promise in clinical trials. This report is the… 
Highly Cited
2001
Highly Cited
2001
Akt, MAPK (Erk1/2), and p38 Act in Concert to Promote Apoptosis in Response to ErbB Receptor Family Inhibition*
The ErbB receptor family is implicated in the malignant transformation of several tumor types and is overexpressed frequently in… 
Highly Cited
2000
Highly Cited
2000
Radiosensitization of human breast cancer cells by a novel ErbB family receptor tyrosine kinase inhibitor.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)